A press release from California Trim Clinic, a Westlake Village wellness and medical weight-management business, promotes a new article in its own editorial publication examining NAD+, copper peptides and what the clinic calls the Hollywood Glow Stack. The stack, as the release describes it, is tirzepatide plus NAD+ plus a GLOW Blend of GHK-Cu, BPC-157 and TB-500.

For readers meeting those terms for the first time: NAD+ is nicotinamide adenine dinucleotide, a naturally occurring coenzyme involved in cellular energy metabolism. GHK-Cu is a copper-binding peptide studied in skin and tissue biology, BPC-157 is described in the release as investigational and examined primarily in preclinical research, and TB-500 is discussed in emerging tissue and repair research. Tirzepatide is a prescription drug acting on GIP and GLP-1 receptors, with FDA-approved products carrying established indications including chronic weight management for eligible patients.

The celebrity on-ramp

The release credits public figures with putting this vocabulary in circulation, noting that Gwyneth Paltrow has publicly discussed NAD+ therapy and that Hailey Bieber has spoken about peptides including GHK-Cu and BPC-157. It then says understanding the science requires looking beyond celebrity experiences, which is the correct note to strike and a slightly odd one to strike in a document that leads with two famous names.

What the clinic concedes

The interesting content here is in the disclaimers, and there are a lot of them. The release states plainly that the Hollywood Glow Stack is an educational concept, not an FDA-approved or clinically validated combination treatment, and that the individual ingredients should not be assumed to have established benefits when combined.

It also says injectable NAD+ and the GLOW Blend are not FDA-approved for the wellness uses discussed, that their safety and effectiveness for those purposes have not been established, and that the FDA has identified safety concerns associated with certain compounded peptides and injectable NAD+ preparations. On NAD+ specifically, the release distinguishes the coenzyme's established biological role from any demonstration that administering more of it produces cosmetic, energy or anti-aging effects.

Where this leaves the stack

A company explaining why its own flagship concept is unvalidated is worth noticing, and the distinction it draws between a compound's biology and a treatment's evidence is the right one. What the release does not offer is a single trial of the combination, because by its own account none exists.